Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (72)

I-01Thomas Dumortier

Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development

Wednesday 10:20-11:40

I-02Mike Dunlavey

A new language for complex ODE models

Wednesday 10:20-11:40

I-03Sulav Duwal

Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1

Wednesday 10:20-11:40

I-04Lisa Ehmann

Pharmacokinetics of meropenem in critically ill patients with varying renal function

Wednesday 10:20-11:40

I-05Miro Eigenmann

PBPK modeling approach to study the impact of lymph flow on the biodistribution of therapeutic antibodies

Wednesday 10:20-11:40

I-06

A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer

Wednesday 10:20-11:40

I-07Yumi Yamamoto

Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data

Wednesday 10:20-11:40

I-08Gregory Ferl

Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics

Wednesday 10:20-11:40

I-09

Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical

Wednesday 10:20-11:40

I-10Natalie Filmann

Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation

Wednesday 10:20-11:40

I-11Linda Franken

Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients

Wednesday 10:20-11:40

I-12Jonathan French

A case study in comparing cognitive development across populations

Wednesday 10:20-11:40

I-13Nicolas Frey

Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab

Wednesday 10:20-11:40

I-14Aline Fuchs

Simulations to simplify gentamicin dosing regimens for neonates and young infants when referral is not possible in developing countries

Wednesday 10:20-11:40

I-15Saskia Fuhrmann

Generic PBPK model to predict preclinical and clinical PK of antibodies

Wednesday 10:20-11:40

I-16María García-Cremades

A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer

Wednesday 10:20-11:40

I-17Peter Gennemark

Unravelling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor-antidote) using mouse data

Wednesday 10:20-11:40

I-18Eva Germovsek

Pharmacokinetic-pharmacodynamic (PKPD) modelling of meropenem in plasma and cerebrospinal fluid (CSF) in infants with late-onset sepsis and/or bacterial meningitis

Wednesday 10:20-11:40

I-19

PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration

Wednesday 10:20-11:40

I-20Ekaterina Gibiansky

Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL)

Wednesday 10:20-11:40

I-21Leonid Gibiansky

vc-MMAE antibody-drug conjugates: a unified model describes pharmacokinetics of eight different compounds

Wednesday 10:20-11:40

I-22Anais Glatard

Influence of UGT2B7 polymorphism on varenicline clearance in a cohort of smokers from the general population

Wednesday 10:20-11:40

I-23Britta Goebel

Modeling & Simulation of Long-Term Body Weight Loss during Obesity Pharmacotherapy

Wednesday 10:20-11:40

I-24Bojana Golubovic

Population modelling of sirolimus data available from routine therapeutic drug monitoring

Wednesday 10:20-11:40

I-25Ignacio Gonzalez-Garcia

Assessment of in vitro dissolution specifications based on an IVIVC and in vivo bioequivalence criteria

Wednesday 10:20-11:40

I-26Verena Gotta

Characterizing age-dependency of cytokine levels in healthy children

Wednesday 10:20-11:40

I-27

Item Response Modeling to Leverage Data from Historical Parkinson’s Disease Trials while Integrating Data from a Newer Version of the Clinical Endpoint

Wednesday 10:20-11:40

I-28Sebastiaan Goulooze

Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours.

Wednesday 10:20-11:40

I-29Sylvain Goutelle

A nonparametric, multiple-model approach to optimize initial dosing and attainment of a target exposure interval: application to busulfan in pediatrics

Wednesday 10:20-11:40

I-30Joachim Grevel

Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC)

Wednesday 10:20-11:40

I-31Monia Guidi

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Wednesday 10:20-11:40

I-32Elham Haem

Adjusted adaptive lasso for covariate model building in nonlinear mixed effects models

Wednesday 10:20-11:40

I-34Janelle Hajjar

Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test

Wednesday 10:20-11:40

I-35Nayoung Han

Dose estimation based on population pharmacokinetic/pharmacogenetic modeling for enteric-coated mycophenolate sodium in kidney transplant recipients

Wednesday 10:20-11:40

I-36Nina Hanke

Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin

Wednesday 10:20-11:40

I-37Fangran Hao

Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft

Wednesday 10:20-11:40

I-38Paul Healy

Model-based dose selection of tocilizumab for the prevention of reperfusion injury.

Wednesday 10:20-11:40

I-39Michael Heathman

A Categorical Time Course PKPD Model Describing the Effect of Ixekizumab on Improvement from Baseline in Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis

Wednesday 10:20-11:40

I-40Andrea Henrich

PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model

Wednesday 10:20-11:40

I-41Christoph Hethey

Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays

Wednesday 10:20-11:40

I-42Jennifer Hibma

Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients

Wednesday 10:20-11:40

I-43Eef Hoeben

Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir

Wednesday 10:20-11:40

I-44Christian Hollensen

Estimation of random variance in NONMEM using different approaches

Wednesday 10:20-11:40

I-45Xiao Hu

Population pharmacokinetic analysis of fampridine in Japanese patients with multiple sclerosis in a Phase 3 study

Wednesday 10:20-11:40

I-47Stephen Duffull

The influence of parameterisation on local identifiability

Wednesday 10:20-11:40

I-48Manuel Ibarra

Pharmacokinetic characterization of naphtalophos in lambs by modelling blood acetylcholinesterase activity, a K-PD model

Wednesday 10:20-11:40

I-49Moustafa M. A. Ibrahim

Importance of hot glucose for the integrated glucose-insulin minimal model

Wednesday 10:20-11:40

I-50Diane-Charlotte Imbs

Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer

Wednesday 10:20-11:40

I-51Itziar Irurzun-Arana

Attractor analysis of Boolean models for Systems Pharmacology Networks

Wednesday 10:20-11:40

I-52Swati Jaiswal

Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters

Wednesday 10:20-11:40

I-53Masoud Jamei

Time variation in the fractional contribution of an enzyme to elimination of a victim drug can explain differences in DDI susceptibility following single and multiple dosing

Wednesday 10:20-11:40

I-54Félix Jaminion

Use of a drug-drug interaction study with itraconazole to quantify the effects of an NME on QT interval duration

Wednesday 10:20-11:40

I-55Carl Johansson

Omeprazole dose recommendation in pediatric patients aged 1-11 months with erosive esophagitis

Wednesday 10:20-11:40

I-56Jong Bong Lee

Predicted versus experimental permeability data for incorporation into GastroPlus™ for modelling and simulations

Wednesday 10:20-11:40

I-57Daniel Jonker

Personalized dosing of a novel recombinant human FSH, follitropin delta, based on individual patient characteristics

Wednesday 10:20-11:40

I-58Marija Jovanovic

Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients

Wednesday 10:20-11:40

I-59Matts Kågedal

Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study.

Wednesday 10:20-11:40

I-60Tatiana Karelina

Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model

Wednesday 10:20-11:40

I-61Anhye Kim

Population Pharmacokinetic/Pharmacoynamic Models to evaluate the positive and delayed effect of escitalopram on QT prolongation

Wednesday 10:20-11:40

I-62

Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients

Wednesday 10:20-11:40

I-63Lena Klopp-Schulze

Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations

Wednesday 10:20-11:40

I-64Katrine Knøsgaard

A model-based approach for joint analysis of pain intensity and opioid consumption in postoperative pain

Wednesday 10:20-11:40

I-65Gilbert Koch

Facilitate treatment adjustment after accidental overdosing: pharmacometric modelling to support clinical practice

Wednesday 10:20-11:40

I-66Anders Kristoffersson

Design and Interim Evaluation of a Sparse Sampling Schedule for Estimation of Individual Colistin Pharmacokinetics

Wednesday 10:20-11:40

I-67

PECAN, a Shiny application for calculating confidence and prediction intervals for pharmacokinetic and pharmacodynamic models

Wednesday 10:20-11:40

I-68Manish Kumar

Elucidating metabolic variations in gut microbiota during health and malnutrition based on genome scale metabolic modeling approach

Wednesday 10:20-11:40

I-69

A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015

Wednesday 10:20-11:40

I-70

Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid

Wednesday 10:20-11:40

I-71Silvia Maria Lavezzi

Structural and practical identifiability of some mPBPK-TMDD models

Wednesday 10:20-11:40

I-72Jean Lavigne

Modeling and simulation of smear count after administration of Eurartesim® (piperaquine (PQ) tetraphosphate/dihydroartemisinin (DHA)) in infected patients with Plasmodium falciparum malaria

Wednesday 10:20-11:40

I-73Mary Lavy

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS)

Wednesday 10:20-11:40

I-74Robert Leary

An Improved Framework for Shrinkage Computations in NLME Population Models

Wednesday 10:20-11:40